Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
AMLODIPINE IN CHRONIC STABLE ANGINA - RESULTS OF A MULTICENTER DOUBLE-BLIND CROSSOVER TRIAL
Autore:
EZEKOWITZ MD; HOSSAK K; MEHTA JL; THADANI U; WEIDLER DJ; KOSTUK W; AWAN N; GROSSMAN W; BOMMER W;
Indirizzi:
YALE UNIV,SCH MED,DEPT MED,3FMP,33 CEDAR ST,POB 3333 NEW HAVEN CT 06510 UNIV COLORADO,DEPT MED DENVER CO 80202 DEPT VET AFFAIRS MED CTR,DEPT MED W HAVEN CT 00000 UNIV FLORIDA,DEPT MED GAINESVILLE FL 00000 UNIV OKLAHOMA,DEPT MED OKLAHOMA CITY OK 00000 UNIV MIAMI,SCH MED,DEPT MED CORAL GABLES FL 33124 UNIV WESTERN ONTARIO HOSP,DEPT MED LONDON ON CANADA UNIV CALIF LOS ANGELES,DEPT MED LOS ANGELES CA 90024 UNIV CALIF DAVIS,DEPT MED DAVIS CA 00000 CHARLESTON CARDIOL ASSOC,DEPT MED CHARLESTON SC 00000
Titolo Testata:
The American heart journal
fascicolo: 3, volume: 129, anno: 1995,
pagine: 527 - 535
SICI:
0002-8703(1995)129:3<527:AICSA->2.0.ZU;2-1
Fonte:
ISI
Lingua:
ENG
Soggetto:
SILENT-MYOCARDIAL-ISCHEMIA; PHARMACOKINETIC PROPERTIES; DAILY LIFE; NIFEDIPINE; PECTORIS; THERAPY; HYPERTENSION; PROPRANOLOL; BEPRIDIL; DISEASE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
25
Recensione:
Indirizzi per estratti:
Citazione:
M.D. Ezekowitz et al., "AMLODIPINE IN CHRONIC STABLE ANGINA - RESULTS OF A MULTICENTER DOUBLE-BLIND CROSSOVER TRIAL", The American heart journal, 129(3), 1995, pp. 527-535

Abstract

The efficacy and safety of amlodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study. The trial consisted of an initial 2-week single-blind placebo period followed by a first period of 4 weeks of double-blind therapy, which was followed by a 1 week washout period and then a second 4-week double-blind period after treatments were crossed over. Twenty-four-hour Holter electrocardiographic monitoring was carried out in 12 patients at three centers. In the first double-blind period amlodipine produced a significantly greater increase in symptom-limited exercise duration (amlodipine478.5 to 520.6 vs placebo 484.6 to 485.2 seconds; change +8.8% vs +0.1%, respectively; p = 0.0004) and total work (amlodipine 2426 to 2984 vs placebo 2505 to 2548 kilopondmeters; change +24% vs +1.7%, respectively; p = 0.0006) and a decrease in angina attack frequency (from 3 to1 per week; p = 0.016) and nitroglycerin consumption (from 2 to 0.5 tablets/wk; p = 0.01) compared with placebo. Holter monitoring revealedsignificant reductions in numbers (amlodipine 4.65 to 2.22 vs placebo1.84 to 1.54; change -52% vs +84%, respectively; p = 0.06), absolute total area (amlodipine 87.66 to 11.43 vs placebo 5.76 to 35.24; change-87% vs +513%, respectively; p = 0.02), and duration (amlodipine 12.29 to 2.95 vs 1.66 to 7.14 seconds; change -76% vs +367%, respectively;p = 0.008) of ST-segment depressions after treatment with amlodipine compared with placebo. After the treatments were crossed over changes continued to favor amlodipine. However, there were no significant changes by Holter monitoring in any of the ST-segment parameters during the period after the crossover. The smaller changes with amlodipine during the period after the crossover may be the result of the long half-life of amlodipine or an exercise training effect. The most frequently reported side effects with amlodipine were headache (11%) and edema (8%). We conclude that amlodipine therapy is well tolerated and that it demonstrates antiischemic and antianginal efficacy in the management of stable angina.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/12/20 alle ore 14:11:30